| Previous Close | 33.620 |
| Open | 33.470 |
| Bid | 33.510 x 4600 |
| Ask | 33.520 x 7800 |
| Day's Range | 33.335 - 33.700 |
| 52 Week Range | 29.830 - 37.390 |
| Volume | 7,498,751 |
| Avg. Volume | 20,637,846 |
| Market Cap | 200.21B |
| Beta | 1.07 |
| PE Ratio (TTM) | 28.24 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.84%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Investopedia•36 minutes ago
Pfizer Downgraded on Patent Expiration for Viagra: Credit Suisse
Analysts downgrade PFE as they suggest that the big pharma stock has limited drivers of upside.
- Investor's Business Daily•4 hours ago
Tesla Started At Neutral, High Risk; Amazon Gets Price Target Hike
Citigroup on Thursday initiated coverage of electric car maker Tesla at neutral/high risk. Analysts also upgraded PC and printer maker HP and athletic apparel vendor Nike.
- Barrons.com•4 hours ago
Pfizer: We Still Like You But…
Shares of Pfizer (PFE) have gained 5.1% since closing at $32 on June 7, and the stock even looks like it had been making a run for the top of its recent range. In fact, they call themselves "long-time supporters" of the company, and see "opportunities for upside over the long term." So why are they downgrading Pfizer?
